| 张华,孙李妍.伊沙佐米联合来那度胺对多发性骨髓瘤病人疗效及血清血小板生成素水平的影响[J].安徽医药,2025,29(11):2321-2324. |
| 伊沙佐米联合来那度胺对多发性骨髓瘤病人疗效及血清血小板生成素水平的影响 |
| The effect of isozomi combined with lenalidomide on the efficacy and serum thrombopoietin levels in patients with multiple myeloma |
| |
| DOI：10.3969/j.issn.1009-6469.2025.11.044 |
| 中文关键词: 多发性骨髓瘤 伊沙佐米 来那度胺 血小板生成素 免疫功能 合来，水， |
| 英文关键词: Multiple myeloma Ixazomib Lenalidomide Thrombopoietin Immunity |
| 基金项目: |
|
| 摘要点击次数: 466 |
| 全文下载次数: 156 |
| 中文摘要: |
| 目的探讨伊沙佐米联合来那度胺对多发性骨髓瘤( MM)病人疗效及血清血小板生成素( TPO)水平的影响。方法择 2020年 1月至 2022年 9月烟台市烟台山医院分别进行来那度胺( A组， 47例)、伊沙佐米( B组， 47例)和伊沙佐米联合来那度选胺(C组， 47例)治疗的 141例 MM病人进行回顾性分析，收集病人的临床资料并比较三组病人的临床疗效、血清 TPO水平、免疫功能指标的变化及不良反应的发生率。结果 C组的总有效率显著高于 A组、 B组( 91.49%比 72.34%、68.09%，P<0.05)，且 A组与 B组之间的总有效率差异无统计学意义( P>0.05)。治疗后， A、B、C三组 MM病人血清 TPO［( 17.06±3.87)ng/L比( 29.32±6.51)ng/L、(17.86±4.12)ng/L比( 28.98±6.44)ng/L、(10.85±2.06)ng/L比( 28.85±6.33)ng/L］、 CD8+均低于治疗前(均 P<0.05)，CD4+均高于治疗前(均 P<0.05)且上述指标 C组改变的程度更为明显(均 P<0.05)A组与 B组之间均差异无统计学意义(均 P>0.05)。结论伊沙佐米联那度胺治疗 MM的效果确切，可降低病人血清 TPO平，并改善病人免疫功能。 |
| 英文摘要: |
| Objective To investigate the impacts of ixazomib combined with lenalidomide on the efficacy and serum thrombopoietin(TPO) level in patients with multiple myeloma (MM).Methods A retrospective analysis was conducted on 141 MM patients who re-ceived treatment with lenalidomide (Group A, 47 cases), isazomib (Group B, 47 cases), and a combination of isazomib and lenalidomide(Group C, 47 cases) at Yantai Mountain Hospital, Yantai City from January 2020 to September 2022. The clinical data of the patientswere collected and the clinical efficacy, serum TPO level, changes in immune function indexes and the incidence of adverse reactionswere compared among the three groups.Results The total effective rate of Group C was significantly higher than that of Group A and Group B (91.49% vs. 72.34%, 68.09%, P<0.05), and there was no statistically significant difference in the total effective rate between Group A and Group B (P>0.05). After treatment, the serum TPO [(17.06±3.87) ng/L vs. (29.32±6.51) ng/L, (17.86±4.12) ng/L vs. (28.98±6.44) ng/L, (10.85±2.06) ng/L vs. (28.85±6.33) ng/L], CD8+ of MM patients in groups A, B, and C were lower than before treat-ment (all P<0.05), while CD4+ were higher than before treatment (all P<0.05), and the degree of change in Group C of the above indica-tors was more significant (all P<0.05). There was no statistically significant difference between Group A and Group B (P>0.05).Conclu. sion Isazzomil combined with lenalidomide is effective in the treatment of MM, which can reduce serum TPO level and improve theimmune function of patients. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
